浙江尖峰集团股份有限公司关于子公司获得药物临床试验批准通知书的公告

Core Viewpoint - The company has received a clinical trial approval notice for its drug JFAN-1001, which is not expected to have a significant impact on its recent operating performance [1][2]. Drug Information - JFAN-1001 mesylate capsules are a new anti-tumor drug developed by the company, classified as a Class 1 chemical drug, indicated for locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-T790M secondary mutation [2]. - The clinical trial application for JFAN-1001 in combination with crizotinib soft capsules was accepted on September 8, 2025, and is currently undergoing Phase II clinical trials in China [2]. - The drug has also received clinical trial approval from the U.S. Food and Drug Administration [2]. Company Impact - The approval of the clinical trial is not expected to significantly affect the company's recent operating performance [1][2]. - The company acknowledges the uncertainties associated with drug development, including the lengthy and complex process from research to market, which may impact clinical trial progress and results [2].